<DOC>
	<DOC>NCT01701739</DOC>
	<brief_summary>This open-label, two-period, fixed-sequence study will investigate the pharmacokinetics and safety of multiple doses of aleglitazar on a single dose of digoxin in healthy volunteers. In period 1, volunteers will receive a single dose of digoxin, in period 2 volunteers will receive multiple doses of aleglitazar and a single dose of digoxin. The anticipated time on study treatment is one month.</brief_summary>
	<brief_title>A Pharmacokinetics Study of Aleglitazar in Combination With Digoxin in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Digoxin</mesh_term>
	<criteria>Healthy volunteers, 1855 years of age, inclusive Body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive. Females must be either surgically sterile or postmenopausal for at least one year or, if they are of childbearing potential, must use two acceptable methods of contracepetion Volunteer normally drinks no more than three cups of coffee/tea/caffeinated soft drinks per day and is willing to stop drinking coffee/tea/caffeinated soft drinks during the study Any clinically relevant abnormal laboratory test results at screening or on Day 1 Has taken any prescribed or herbal/over the counter medication within 2 weeks prior to the first dosing A history of clinically significant gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematological, psychiatric, renal, hepatic, bronchopulmonary or neurological conditions or lipid metabolism disorders. Infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C An average alcohol intake of more than 14 units per week A known permanent or unexplained elevation of serum transaminases &gt; 1.5 times the upper limit of normal A positive screen for drugs of abuse Acute infection requiring treatment within 4 weeks prior to screening Diagnosed or treated malignancy within the past 5 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>